Navigation Links
Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Date:6/15/2010

THE WOODLANDS, Texas, June 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will be presenting clinical data from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010: The 92nd Annual Meeting and Expo, June 19 – 22, 2010 in San Diego, California and the 70th Scientific Sessions of the American Diabetes Association, June 25 – 29, 2010 in Orlando, Florida.

ENDO 2010: The 92nd Annual Meeting and Expo

David Powell, M.D., Lexicon's senior vice president of metabolism research, will give a presentation at ENDO 2010 titled "LX4211, a Dual SGLT1 and SGLT2 Inhibitor, Shows Rapid and Significant Improvement in Glycemic Control over 4 Weeks in Patients with Type 2 Diabetes Mellitus" on Monday, June 21, 2010 at 11:15 a.m. Pacific Time.  

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Decoding the dictionary: Study suggests lexicon evolved to fit in the brain
2. Heart of Herschel to be presented to media
3. Frontiers in Optics presents scientific advancements
4. Male contraception breakthroughs to be presented, Seattle Sept. 27-28
5. New book presents successful strategies for probing genetic variation
6. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
7. Chemical compound present in detergents produce bacteria alterations in agricultural soils
8. New book presents methods to poke and prod individual molecules
9. Present-day species of piranha result from a marine incursion into the Amazon Basin
10. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
11. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , ... it will showcase its EyeLock ID technology integrated in a ... Energy,s Oak Ridge National Laboratory (ORNL) at the ... identity authentication technology is being used to validate the driver ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... today announced a series of important changes ... anti-inflammatory class of drugs, including COX-2 selective ... NSAID medications. A list of these products ... , "Today's actions protect and advance the ...
... Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have ... mutated gene that causes inherited cases of amytrophic lateral ... progression rate of the fatal motor neuron disease. Their ... Nature Medicine, and in the journal's advanced online publication ...
... Hughes Medical Institute researchers chiseling away at the problem ... how the drugs' main cellular target in bacteria evolves ... findings are already leading to new experimental antibiotics that ... major worldwide health problem. , Led by Thomas A. ...
Cached Biology News:FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2Silence the gene, save the cell: RNA interference as promising therapy for ALS 2Silence the gene, save the cell: RNA interference as promising therapy for ALS 3Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
(Date:2/26/2015)... , Feb. 26, 2015 BioEnterprise today announced ... have attracted more than $2 billion in growth funding ... and national investors, strategic sources, state – including the ... of the $2 billion has been raised in the ... on the heels of the BioEnterprise Midwest Healthcare ...
(Date:2/26/2015)... 2015 Innovation is more urgent ... unexpected parts of the world and transforming global ... to manufacturing to health care, disruption is constantly ... and socio-political trends shake the foundations of established ... for CEOs to survive the next wave of ...
(Date:2/26/2015)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... are used to develop, manufacture and sell enzymes ... biopharmaceutical and industrial enzyme industries, announced today that ... ending December 31, 2014 after market close on ... conference call that day at 5:00 p.m. Eastern ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3
... WYE ),announced today that it will present at ... 21, 2008 at 10:30 a.m. Eastern,Time. Presenting for Wyeth ... Officer, Wyeth., Wyeth,s presentation will be webcast live ... following the conference., Wyeth is one of the ...
... FORT WORTH, Texas, May 16 George Abercrombie, ... more than 200,Fort Worth business leaders today at ... threat of a pandemic flu presents businesses with ... "While businesses are all too familiar with ...
... Metametrix Institute (, http://www.metametrixinstitute.org ) announced ... Functional Medicine, 2nd,Edition, written and edited by Richard ... the original edition by Bralley and Lord, Laboratory,Evaluations ... is the,new educational arm of Metametrix Inc., a ...
Cached Biology Technology:CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans 2CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans 3Introducing Laboratory Evaluations for Integrative and Functional Medicine 2
... SuperScript™ III RNase H- ... an improved version of ... RT. Like SuperScript™ II ... DNA strand from single-stranded ...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
... DNA Ligation Kit enables ligation ... fragments in just 5 min ... on the DNA concentration, either ... concatemeric (high DNA concentration) ligation ...
... Thermo Labsystems Nepheloskan Ascent is ... to measurement in microplates. Nepheloskan ... an ultra-sensitive technique for particle ... for solubility testing in drug ...
Biology Products: